Company intelligence / Profile preview

New Path Bio

Ownership: Private
Development stage: Preclinical

Overview

New Path Bio pioneers precision fermentation to produce cost-effective, nutritious, and bioactive proteins from microbes. Their patented technology converts industrial waste streams into high-value proteins designed to support optimal wellbeing. The company focuses on sustainable production methods that do not require animals, land, or significant water resources.[1][2][3]

They are not a therapeutics/drug developer but rather a platform company in the alternative protein/nutrition space.

No clinical results as they do not develop pharmaceuticals.

Therapeutic areas: Other
Modalities: Precision fermentationmicrobial proteinsbioactive proteins from microbes[3]
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on New Path Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Path Bio.

Explore the full profile